Table 2.
Comparison of clinical and molecular characteristics in different SPNS2/3 expression groups among chemotherapy-only group.
| Characteristics | SPNS2 | P | SPNS3 | P | |||
|---|---|---|---|---|---|---|---|
| High (n=42) | Low (n=42) | High (n=42) | Low (n=42) | ||||
| Age (years), median (range) | 67.5 (25-88) | 66 (22-81) | 0.975a | 66 (33-88) | 67 (22-81) | 0.982a | |
| Age group, n (%) | 0.814b | 0.814b | |||||
| <60 years | 12 (28.6) | 14 (33.3) | 14 (33.3) | 12 (28.6) | |||
| ≥60 years | 30 (71.4) | 28 (66.7) | 28 (66.7) | 30 (71.4) | |||
| Gender, n (%) | 0.662b | 0.382b | |||||
| Male | 21 (50.0) | 24 (57.1) | 25 (59.5) | 20 (47.6) | |||
| Female | 21 (50.0) | 18 (42.9) | 17 (40.5) | 22 (52.4) | |||
| WBC (×109/L), median (range) |
14.8 (0.7-297.4) |
14.6 (1.9-131.5) |
0.862a | 16.5 (0.7-134.4) |
13.3 (1.0-297.4) |
0.943a | |
| BM blasts (%), median (range) | 73.5 (32-99) |
69.5 (30-95) |
0.455a | 74 (30-98) |
68 (32-99) |
0.785a | |
| PB blasts (%), median (range) | 49.5 (0-98) |
7.5 (0-90) |
0a | 38 (0-97) |
17.5 (0-98) |
0.149a | |
| FAB subtypes, n (%) | |||||||
| M0 | 6 (14.3) | 1 (2.4) | 0.109b | 3 (7.1) | 4 (9.5) | 1.000b | |
| M1 | 18 (42.9) | 2 (4.8) | 0b | 13 (31.0) | 7 (16.7) | 0.200b | |
| M2 | 13 (31.0) | 8 (19.0) | 0.314b | 9 (21.4) | 12 (28.6) | 0.615b | |
| M4 | 4 (9.5) | 16 (38.1) | 0.004b | 12 (28.6) | 8 (19.0) | 0.443b | |
| M5 | 1 (2.4) | 11 (26.2) | 0.003b | 4 (9.5) | 8 (19.0) | 0.350b | |
| M6 | 0 (0.0) | 1 (2.4) | 1.000b | 1 (2.4) | 0 (0.0) | 1.000b | |
| M7 | 0 (0.0) | 2 (4.8) | 0.494b | 0 (0.0) | 2 (4.8) | 0.494b | |
| Cytogenetics, n (%) | |||||||
| Normal | 19 (45.2) | 21 (50.0) | 0.827b | 22 (52.4) | 18 (42.9) | 0.512b | |
| t(9;22)/BCR-ABL1 | 0 (0.0) | 1 (2.44) | 1.000b | 0 (0.0) | 1 (2.4) | 1.000b | |
| inv(16)/CBFβ-MYH11 | 1 (2.4) | 5 (11.9) | 0.202b | 2 (4.8) | 4 (9.5) | 0.676b | |
| Complex | 7 (16.7) | 5 (11.9) | 0.520b | 7 (16.7) | 4 (9.5) | 0.520b | |
| 11q23/MLL | 1 (2.4) | 2 (4.8) | 1.000b | 2 (4.8) | 1 (2.4) | 1.000b | |
| t(8;12)/RUNX1-RUNX1T1 | 3 (7.1) | 3 (7.1) | 1.000b | 0 (0.0) | 6 (14.3) | 0.026b | |
| Others | 11 (26.2) | 6 (14.3) | 0.277b | 9 (21.4) | 8 (19.0) | 1.000b | |
| Risk, n (%) | |||||||
| Good | 4 (9.5) | 8 (19.0) | 0.350b | 2 (4.8) | 10 (23.8) | 0.026b | |
| Intermediate | 24 (57.1) | 27 (64.3) | 0.655b | 27 (64.3) | 24 (57.1) | 0.655b | |
| Poor | 12 (28.6) | 7 (16.7) | 0.297b | 11 (26.2) | 8 (19.0) | 0.603b | |
| FLT3, n (%) | 0.668b | 0.447b | |||||
| FLT3-ITD | 6 (4.3) | 9 (21.4) | 8 (19.0) | 7 (16.7) | |||
| FLT3-TKD | 9 (9.5) | 3 (7.1) | 5 (11.9) | 2 (4.8) | |||
| Wildtype | 32 (76.2) | 30 (71.4) | 29 (69.0) | 33 (78.6) | |||
| NPM1, n (%) | 0.641b | 0.160b | |||||
| Mutation | 15 (35.7) | 12 (28.6) | 17 (40.5) | 10 (23.8) | |||
| Wildtype | 27 (64.3) | 30 (71.4) | 25 (59.5) | 32 (76.2) | |||
| DNMT3A, n (%) | 0.625b | 0.141b | |||||
| Mutation | 13 (31.0) | 10 (23.8) | 15 (35.7) | 8 (19.0) | |||
| Wildtype | 29 (69.0) | 32 (76.2) | 27 (64.3) | 34 (81.0) | |||
| IDH1/IDH2, n (%) | 0.570b | 1.000b | |||||
| Mutation | 9 (21.4) | 6 (14.3) | 7 (16.7) | 8 (19.0) | |||
| Wildtype | 33 (78.6) | 36 (85.7) | 35 (83.3) | 34 (81.0) | |||
| RUNX1, n (%) | 0.713b | 1.000b | |||||
| Mutation | 5 (11.9) | 3 (7.1) | 4 (9.5) | 4 (9.5) | |||
| Wildtype | 37 (88.1) | 39 (92.9) | 38 (90.5) | 38 (90.5) | |||
| NRAS/KRAS, n (%) | 0.756b | 0.756b | |||||
| Mutation | 5 (11.9) | 7 (16.7) | 5 (11.9) | 7 (16.7) | |||
| Wildtype | 37 (88.1) | 35 (83.3) | 37 (88.1) | 35 (83.3) | |||
| TET2, n (%) | 0.194b | 1.000b | |||||
| Mutation | 8 (19.0) | 3 (7.1) | 5 (11.9) | 6 (14.3) | |||
| Wildtype | 34 (81.0) | 39 (92.9) | 37 (88.1) | 36 (85.7) | |||
| TP53, n (%) | 1.000b | 0.520b | |||||
| Mutation | 5 (11.9) | 6 (14.3) | 7 (16.7) | 4 (9.5) | |||
| Wildtype | 37 (88.1) | 36 (85.7) | 35 (83.3) | 38 (90.5) | |||
| Relapse/n (%) | 0.261b | 0.822b | |||||
| Yes | 13 (31.0) | 19 (45.2) | 15 (37.5) | 17 (40.5) | |||
| No | 29 (69.0) | 23 (54.8) | 27 (64.3) | 25 (59.5) | |||
WBC white blood cell, BM bone marrow, PB peripheral blood, FAB French American British
aMann-Whitney U-test
bChi-square test